Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Time period What may be noticeable What the evidence supports Weeks 1-4 Satiety, appetite changes, nausea, bowel changes, early scale movement Early tolerability period, not the main efficacy endpoint window Weeks 4-12 More consistent appetite suppression and early weight trend Direction of response may become clearer, but individual variance is high Weeks 12-24 Clinically meaningful separation becomes easier to evaluate Phase 2 primary endpoint at 24 weeks showed dose-dependent weight loss Weeks 24-48 Major body-weight reduction window in Phase 2 48-week Phase 2 secondary endpoint showed the largest published Phase 2 changes Weeks 68-104 Longer-term Phase 3 and extension outcomes TRIUMPH program endpoints measure durability over longer windows Weeks 1-4: Early Signals, Not Final Results The first few weeks are usually the wrong window for judging full retatrutide results
Sustained weight loss observed The SURMOUNT-1 trial reported significant weight loss with tirzepatide use
Rosie G
In type 2 diabetes, either the body stops producing enough insulin or there is resistance to the action of insulin
